Advances in transfusion science for shock-trauma: Optimising the clinical management of acute haemorrhage

Transfusion and Apheresis Science

Volumn 53, Issue 3, 2015, Pages 412-422

  Seghatchian, Jerard ^a   Putter, Jeffrey S ^b  

^a International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

^b Medical Biomechanics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ACIDOSIS; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BLUNT TRAUMA; CLINICAL PROTOCOL; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE TRANSFUSION; HEMODILUTION; HEMORRHAGIC SHOCK; HUMAN; HYPOTHERMIA; INJURY SEVERITY; NONHUMAN; PATHOPHYSIOLOGY; PENETRATING TRAUMA; RESUSCITATION; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; ACUTE DISEASE; ADVERSE EFFECTS; BLOOD; BLOOD COMPONENT THERAPY; PROCEDURES; SHOCK, HEMORRHAGIC; WOUNDS AND INJURIES;

ACUTE DISEASE; BLOOD COMPONENT TRANSFUSION; HUMANS; RESUSCITATION; SHOCK, HEMORRHAGIC; WOUNDS AND INJURIES;

EID: 84983208837     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2015.11.012     Document Type: Review

References (43)

1. Lancet 2010.
2. Hess J.T., et al. TRASCI 2013.
3. Lavee J., et al. JTCS 1989.
4. Brohi K. Hem-15: developing transfusion based strategies for optimising outcomes following mass casualty events using a discrete event simulation modelling approach. Shock 2015, 44(Suppl. 2):5-6.
5. Rahbar E., et al. Trauma, time, and transfusions: a longitudinal analysis of coagulation markers in severely injured trauma patients receiving modified whole blood or component blood products. Shock 2015, 44(5):417-425. 10.1097/SHK.0000000000000449.
6. Trasci 2014, 51:105-110.
7. Salomon C., et al. Clin Lab Inves 2015, 1-8.
8. Heler H.E., et al. Use of tranexamic acid in bleeding combat casualties. Mil Med 2015, 180:844-846.
9. Brohi K. Hem-11: tranexamic acid is associated with enhanced clot strength, reduced fibrinolysis and reduced acute traumatic coagulopathy in bleeding trauma patients. Shock 2015, 44(Suppl. 2):4. 10.1097/01.
10. D'Alessandro A., et al. Red blood cell metabolism under prolonged anaerobic storage. Mol Biosyst 2013, 9(6):1196-1209.
11. Free Rad Bio Med 2014.
12. Pallotta V., et al. Storing red blood cells with vitamin C and N-acetylcysteine prevents oxidative stress-related lesions: a metabolomics overview. Blood Transfus 2014, 12(3):376-387.
13. D'Alessandro A., et al. Early hemorrhage triggers metabolic responses that build up during prolonged shock. Am J Physiol 2015, 10.1152/ajpregu.00030.2015.
14. Gould S., et al. Packed red blood cell transfusion in the intensive care unit: limitations and consequences. Am J Crit Care 2007, 16:39-48.
15. Holcomb J.B., et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008, 248:447-458.
16. Inoba K., et al. Optimal positioning for emergent needle thoracostomy: a cadaver-based study. J Trauma 2011, 71:1099-1103.
17. Pati S., et al. Protective effects of fresh frozen plasma on vascular endothelial permeability, coagulation, and resuscitation after hemorrhagic shock are time dependent and diminish between days 0 and 5 after thaw. J Trauma 2010, 69:S55-63.
18. Deng X., et al. Adiponectin in fresh frozen plasma contributes to restoration of vascular barrier function after hemorrhagic shock. Shock 2015, 10.1097/SHK.0000000000000458.
19. Lovejoy A.E., et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006, 108(1):57-62.
20. J Am Coll Surg 2007.
21. Sina A., et al. Thrombelastography and rotational thromboelastometry early amplitudes in 182 trauma patients with clinical suspicion of severe injury. J Trauma Acute Care Surg 2014, 76:682-690.
22. Espinoso A., Seghatchian J. What is happening? The evolving role of the blood bank in the management of the bleeding patient: the impact of TEG as an early diagnostic predictor for bleeding. Transfus Apher Sci 2014, 51:105-110.
23. Pidcore H.F. J Trauma Acute Care Surg 2012.
24. Lopez-Vilchez I., et al. Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol 2011, 178:2938-2948.
25. Schlimp C.J., et al. Recovery of fibrinogen concentrate after intraosseous application is equivalent to the intravenous route in a porcine model of hemodilution. J Trauma Acute Surg 2014, 76:1235-1242.
26. D'Alessandro A., et al. Time-course investigation of SAGM-stored leukocyte-filtered red blood cell concentrates: from metabolism to proteomics. Hematologica 2012, 97:107-115.
27. Jozwik M., et al. Antioxidant defence of red blood cells and plasma in stored human blood. Clin Chim Acta 1997, 267:129-142.
28. Pallotta V., et al. Supplementation of anti-oxidants in leucofiltered erythrocyte concentrates: assessment of morphological changes through scanning electron microscopy. Blood Transfus 2014, 12:421-424. 10.2450/2014.0272-13.
29. Seghatchian J. Multilayer-strategy to enhance optimal safety of the blood supply: the role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: moderator views. Transfus Apher Sci 2015, 52(2). 10.1016/j.transci.2015.02.011.
30. Seghatchian J. Highlights of the role of PMP in health & disease & advancements in PRT and quality in transfusion establishments. Transfus Apher Sci 2014, 52(1). 10.1016/j.transci.2014.12.014.
31. Espinosa A., Seghatchian J. The evolving role of the blood bank in the management of the bleeding patient: the impact of TEG as an early diagnostic predictor for bleeding. Transfus Apher Sci 2014, 51(3). 10.1016/j.transci.2014.10.017.
32. Klausen S.S., Hervig T., Seghatchian J. Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. Transfus Apher Sci 2014, 51(2). 10.1016/j.transci.2014.08.007.
33. Hervig T., Kaada S., Seghatchian J. Storage and handling of blood components - perspectives. Transfus Apher Sci 2014, 51(2). 10.1016/j.transci.2014.10.001.
34. Burnouf T., Goubran H.A., Seghatchian J. Multifaceted regenerative lives of expired platelets in the second decade of the 21st century. Transfus Apher Sci 2014, 51(2). 10.1016/j.transci.2014.08.006.
35. Seghatchian J., Putter J.S. Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci 2013, 49(2). 10.1016/j.transci.2013.07.023.
36. Seghatchian J., Samama M.M. Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy. Transfus Apher Sci 2012, 47(2):235-243. 10.1016/j.transci.2012.06.001.
37. Seghatchian J., Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apher Sci 2012, 46(2):221-229. 10.1016/j.transci.2012.01.008.
38. Seghatchian J., Hervig T., Putter J.S. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates. Transfus Apher Sci 2011, 45(1):75-84. 10.1016/j.transci.2011.06.006.
39. Spinella P.C., Strandenes G., Rein E.B., Seghatchian J., Hervig T. Symposium on fresh whole blood for severe hemorrhagic shock: from in-hospital to far forward resuscitations. Transfus Apher Sci 2012, 46(1):113-117. 10.1016/j.transci.2012.01.002.
40. Seghatchian J., de Sousa G. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: current status/future trends. Transfus Apher Sci 2008, 37(3):251-259. 10.1016/j.transci.2007.02.007.
41. Seghatchian J., Solheim B.G. Current opinions on safer red cell transfusion practice and the appropriate use of alternative strategies. Transfus Apher Sci 2007, 37(2):201-207. 10.1016/j.transci.2007.09.001.
42. Seghatchian J. Platelet storage lesion: the limited impacts of leukoreduction processes in retention of microvesicules, prion, and platelet-derived biological response modifiers. Transfus Apher Sci 2006, 34(1):86-88. 10.1016/j.transci.2005.09.026.
43. Krailadsiri P., Seghatchian J. Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets. Vox Sanguinis 2000, 78(3):171-175. 10.1046/j.1423-0410.2000.7830171.x.